

# Roger Thompson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2738336/publications.pdf>

Version: 2024-02-01

95  
papers

5,253  
citations

94269

37  
h-index

98622

67  
g-index

102  
all docs

102  
docs citations

102  
times ranked

7780  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	5.2	394
2	MET is required for the recruitment of anti-tumoural neutrophils. <i>Nature</i> , 2015, 522, 349-353.	13.7	359
3	The 2018 Lake Louise Acute Mountain Sickness Score. <i>High Altitude Medicine and Biology</i> , 2018, 19, 4-6.	0.5	324
4	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , 2021, 2, e354-e365.	3.4	216
5	Blocking Macrophage Leukotriene B <sub>4</sub> Prevents Endothelial Injury and Reverses Pulmonary Hypertension. <i>Science Translational Medicine</i> , 2013, 5, 200ra117.	5.8	203
6	Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1-15.	1.4	199
7	VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. <i>Journal of Clinical Investigation</i> , 2009, 119, 1298-1311.	3.9	184
8	Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. <i>Trends in Molecular Medicine</i> , 2017, 23, 31-45.	3.5	171
9	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
10	Mechanical Activation of Hypoxia-Inducible Factor 1 $\alpha$ Drives Endothelial Dysfunction at Atheroprone Sites. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 2087-2101.	1.1	154
11	Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1053-1063.	3.9	147
12	Hypoxia-inducible factor 2 $\alpha$ regulates key neutrophil functions in humans, mice, and zebrafish. <i>Blood</i> , 2014, 123, 366-376.	0.6	124
13	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711.	5.2	122
14	Hypoxia Selectively Inhibits Respiratory Burst Activity and Killing of <i>Staphylococcus aureus</i> in Human Neutrophils. <i>Journal of Immunology</i> , 2011, 186, 453-463.	0.4	116
15	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , 2021, 398, 223-237.	6.3	110
16	Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 458-468.	2.5	99
17	The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800589.	3.1	87
18	Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 341-348.	0.2	85

#	ARTICLE	IF	CITATIONS
19	Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis. <i>Cell Metabolism</i> , 2021, 33, 411-423.e4.	7.2	84
20	Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. <i>Journal of Clinical Investigation</i> , 2017, 127, 3407-3420.	3.9	71
21	Severe Pulmonary Arterial Hypertension Induced by SU5416 and Ovalbumin Immunization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 679-687.	1.4	70
22	Nuclear Factor $\kappa$ B Inhibition Reduces Lung Vascular Lumen Obliteration in Severe Pulmonary Hypertension in Rats. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 413-425.	1.4	65
23	Hypoxia determines survival outcomes of bacterial infection through HIF-1 $\alpha$ -dependent reprogramming of leukocyte metabolism. <i>Science Immunology</i> , 2017, 2, .	5.6	61
24	The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2018, 5, 217.	1.2	61
25	Transient Overexpression of Gremlin Results in Epithelial Activation and Reversible Fibrosis in Rat Lungs. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 870-878.	1.4	60
26	Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. <i>High Altitude Medicine and Biology</i> , 2010, 11, 217-222.	0.5	58
27	HIF-mediated innate immune responses: cell signaling and therapeutic implications. <i>Hypoxia (Auckland, N.Z.)</i> 10, 784-814. doi:10.1080/10742175.2019.1638878	1.9	58
28	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	2.2	58
29	Lung Abnormalities Detected with Hyperpolarized $^{129}\text{Xe}$ MRI in Patients with Long COVID. <i>Radiology</i> , 2022, 305, 709-717.	3.6	57
30	Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 199-210.	2.5	55
31	Endogenous Urate Production Augments Plasma Antioxidant Capacity in Healthy Lowland Subjects Exposed to High Altitude. <i>Chest</i> , 2007, 131, 1473-1478.	0.4	52
32	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 55, 2000041.	3.1	48
33	Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness. <i>PLoS ONE</i> , 2014, 9, e81229.	1.1	48
34	Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 271-284.	0.4	48
35	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594.	2.5	45
36	Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness. <i>Respiratory Medicine</i> , 2007, 101, 587-594.	1.3	39

#	ARTICLE	IF	CITATIONS
37	CXCR4 Inhibition Ameliorates Severe Obliterative Pulmonary Hypertension and Accumulation of C-Kit+ Cells in Rats. <i>PLoS ONE</i> , 2014, 9, e89810.	1.1	38
38	Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1514-1516.	3.1	35
39	Pulmonary Microcirculation in Interstitial Lung Disease. <i>Proceedings of the American Thoracic Society</i> , 2011, 8, 516-521.	3.5	34
40	Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 430-445.	1.1	33
41	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	2.2	33
42	Sildenafil Citrate for the Prevention of High Altitude Hypoxic Pulmonary Hypertension: Double Blind, Randomized, Placebo-Controlled Trial. <i>High Altitude Medicine and Biology</i> , 2011, 12, 207-214.	0.5	32
43	Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. <i>Thorax</i> , 2012, 67, 796-803.	2.7	31
44	Thromboelastometry and Platelet Function during Acclimatization to High Altitude. <i>Thrombosis and Haemostasis</i> , 2018, 118, 063-071.	1.8	30
45	Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. <i>Frontiers in Medicine</i> , 2019, 6, 93.	1.2	30
46	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021, 69, 103444.	2.7	30
47	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021, 57, 2000124.	3.1	29
48	Cigarette smoke exposure aggravates air space enlargement and alveolar cell apoptosis in Smad3 knockout mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 301, L391-L401.	1.3	28
49	Hypoxia, the HIF pathway and neutrophilic inflammatory responses. <i>Biological Chemistry</i> , 2013, 394, 471-477.	1.2	28
50	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001049.	1.2	28
51	Pulmonary hypertension phenotypes in patients with systemic sclerosis. <i>European Respiratory Review</i> , 2021, 30, 210053.	3.0	27
52	When Innate Immunity Meets Angiogenesis—The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension. <i>Frontiers in Medicine</i> , 2020, 7, 352.	1.2	24
53	Mice infected with <i>Mycobacterium tuberculosis</i> are resistant to acute disease caused by secondary infection with SARS-CoV-2. <i>PLoS Pathogens</i> , 2022, 18, e1010093.	2.1	24
54	A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. <i>Nature Communications</i> , 2019, 10, 5183.	5.8	22

#	ARTICLE	IF	CITATIONS
55	Mutations in succinate dehydrogenase B (SDHB) enhance neutrophil survival independent of HIF-1 $\alpha$ expression. <i>Blood</i> , 2016, 127, 2641-2644.	0.6	21
56	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104.	5.8	21
57	NT-proBNP Does Not Rise on Acute Ascent to High Altitude. <i>High Altitude Medicine and Biology</i> , 2008, 9, 307-310.	0.5	20
58	Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation. <i>ELife</i> , 2019, 8, .	2.8	20
59	Endothelial Nitric Oxide Synthase Polymorphisms Do Not Influence Pulmonary Artery Systolic Pressure at Altitude. <i>High Altitude Medicine and Biology</i> , 2006, 7, 221-227.	0.5	19
60	Vascular Repair and Regeneration as a Therapeutic Target for Pulmonary Arterial Hypertension. <i>Respiration</i> , 2013, 85, 355-364.	1.2	16
61	Hypoxic regulation of neutrophil function and consequences for <i>Staphylococcus aureus</i> infection. <i>Microbes and Infection</i> , 2017, 19, 166-176.	1.0	15
62	Clonally selected primitive endothelial cells promote occlusive pulmonary arteriopathy and severe pulmonary hypertension in rats exposed to chronic hypoxia. <i>Scientific Reports</i> , 2020, 10, 1136.	1.6	15
63	Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. <i>ERJ Open Research</i> , 2021, 7, 00046-2021.	1.1	15
64	Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. <i>Heart</i> , 2022, 108, 1392-1400.	1.2	15
65	Endothelial cells are a source of Nestin expression in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2019, 14, e0213890.	1.1	13
66	Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 34-43.	1.5	13
67	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12098.	1.8	13
68	Retinal Vessel Tortuosity in Response to Hypobaric Hypoxia. <i>High Altitude Medicine and Biology</i> , 2012, 13, 263-268.	0.5	12
69	Hypoxia Modulates Platelet Purinergic Signalling Pathways. <i>Thrombosis and Haemostasis</i> , 2020, 120, 253-261.	1.8	12
70	Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3019-3025.	0.7	12
71	Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1271-1272.	2.3	11
72	Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin. <i>ERJ Open Research</i> , 2022, 8, 00596-2021.	1.1	11

#	ARTICLE	IF	CITATIONS
73	A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. <i>Thorax</i> , 2012, 67, 985-992.	2.7	10
74	Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. <i>Respirology</i> , 2020, 25, 1066-1072.	1.3	10
75	Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. <i>ERJ Open Research</i> , 2022, 8, 00503-2021.	1.1	10
76	Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1019-1034.	2.5	10
77	RNA Signaling in Pulmonary Arterial Hypertension—A Double-Stranded Sword. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3124.	1.8	9
78	Manual Assessment of the Initial Fall in Blood Pressure After Orthostatic Challenge at High Altitude. <i>Wilderness and Environmental Medicine</i> , 2008, 19, 225.	0.4	8
79	A local circadian clock calls time on lung inflammation. <i>Nature Medicine</i> , 2014, 20, 809-811.	15.2	8
80	From Here to There, Progenitor Cells and Stem Cells Are Everywhere in Lung Vascular Remodeling. <i>Frontiers in Pediatrics</i> , 2016, 4, 80.	0.9	8
81	Selective improvement of pulmonary arterial hypertension with a dual ET <sub>A</sub> /ET <sub>B</sub> receptors antagonist in the apolipoprotein E <sup>−/−</sup> model of PAH and atherosclerosis. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	0.8	8
82	The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	0.8	7
83	Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 797561.	1.1	7
84	Pericardial effusions in healthy lowlanders after acute ascent to high altitude. <i>Heart</i> , 2005, 92, 539-540.	1.2	6
85	The citric acid cough threshold and the ventilatory response to carbon dioxide on ascent to high altitude. <i>Respiratory Medicine</i> , 2009, 103, 1182-1188.	1.3	5
86	Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. <i>Frontiers in Medicine</i> , 2018, 5, 172.	1.2	4
87	Soluble P-Selectin and von Willebrand Factor Rise in Healthy Volunteers Following Non-exertional Ascent to High Altitude. <i>Frontiers in Physiology</i> , 2022, 13, 825819.	1.3	3
88	Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12019.	0.8	2
89	A complication of peroral bronchoscopy. <i>European Respiratory Journal</i> , 2010, 35, 221-222.	3.1	1
90	A Novel Peptide for Immunomodulation in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1460-1461.	2.5	1

#	ARTICLE	IF	CITATIONS
91	Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future. <i>Frontiers in Medicine</i> , 2020, 7, 125.	1.2	1
92	Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. , 2020, , .		1
93	Catastrophe for a campanologist. <i>European Journal of Emergency Medicine</i> , 2006, 13, 184-186.	0.5	0
94	Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts. <i>Current Respiratory Medicine Reviews</i> , 2012, 8, 116-122.	0.1	0
95	Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. , 2020, , .		0